Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy.

Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC. · 2021

Read Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy. by Yang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC. (2021) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc7864927.txt.

Introduction

Yang and co-authors show how galectin-9 works with PD-1 and TIM-3 to spare worn T cells. Both receptors mark exhausted T cells. Their teamwork was unclear. Galectin-9 is the binding partner for TIM-3.

PD-1 grabs galectin-9 and blunts its kill signal. That shield keeps double-marked T cells alive. Blocking galectin-9 grew killer T cells inside tumors. It also grew suppressive regulator cells, though. Pairing the block with a GITR drug cleared those regulators. The pair then attacked tumors in synergy. High galectin-9 tracks with poor outlook in many cancers. The authors name it a fresh immunotherapy target.

Catalog record

CREATORYang R, Sun L, Li CF, Wang YH, Yao J, Li H, Yan M, Chang WC, Hsu JM, Cha JH, Hsu JL, Chou CW, Sun X, Deng Y, Chou CK, Yu D, Hung MC.
YEAR2021
COLLECTIONPAPERS
FORMATTXT
FILE SIZE87 KB
LICENSECC BY 4.0
RIGHTSCC BY
SOURCEEurope PMC

Source: https://europepmc.org/articles/PMC7864927

Browse the full library · About the Tower of Babel

Full text

The opening of the work, from the library's hosted text:

Galectin-9 interacts with PD-1 and TIM-3 to regulate T cell death and is a target for cancer immunotherapy By Riyao Yang, Linlin Sun, Ching-Fei Li, Yu-Han Wang, Jun Yao, Hui Li, Meisi Yan, Wei-Chao Chang, Jung-Mao Hsu, Jong-Ho Cha, Jennifer L Hsu, Cheng-Wei Chou Published in: Nature Communications DOI: 10.1038/s41467-021-21099-2 ABSTRACT Abstract The two T cell inhibitory receptors PD-1 and TIM-3 are co-expressed during exhausted T cell differentiation, and recent evidence suggests that their crosstalk regulates T cell exhaustion and immunotherapy efficacy; however, the molecular mechanism is unclear. Here we show that PD-1 contributes to the persistence of PD-1+TIM-3+ T cells by binding to the TIM-3 ligand galectin-9 (Gal-9) and attenuates Gal-9/TIM-3-induced cell death. Anti-Gal-9 therapy selectively expands intratumoral TIM-3+ cytotoxic CD8 T cells and immunosuppressive regulatory T cells (Treg cells). The combination of anti-Gal-9 and an agonistic antibody to the co-stimulatory receptor GITR (glucocorticoid-induced tumor necrosis factor receptor-related protein) that depletes Treg cells induces synergistic antitumor activity. Gal-9 expression and secretion are promoted by interferon β and γ, and high Gal-9 expression correlates with poor prognosis in multiple human cancers. Our work uncovers a function for PD-1 in exhausted T cell survival and suggests Gal-9 as a promising target for immunotherapy. Subject terms: Cancer, Cancer immunotherapy, Tumour immunology, Cell biology, Immunology INTRODUCTION CD8 T cells kill tumor cells directly during antitumor immune response, and tumor infiltration of CD8 T cells positively correlates with patient prognosis in a wide range of malignancies1. The frequency and activity of these cells are regulated by a balance of co-stimulatory and co-inhibitory signals that are collectively termed immune checkpoints2. Under normal physiological conditions, immune response is kept in check by immune checkpoints to prevent autoimmunity. However, persistent antigen stimulation in chronic viral infection and cancer leads to T cell exhaustion, a state of T cell dysfunction regulated primarily by the master regulators TOX3 and TCF-14,5, and developed after precursor exhausted T cells (TCF1+PD-1intTIM-3–) differentiate into terminally exhausted T cells (TCF1–PD-1hiTIM-3+)6–10. The programmed cell death protein 1 (PD-1) is one of the most studied immune checkpoints that regulates T cell activity. Upon engagement by its ligand PD-L1, PD-1 recruits the SHP2 tyrosine phosphatase to dephosphorylate critical protein molecules for TCR signaling and T cell activation, such as ZAP-70 and the co-stimulatory receptor CD2811,12, which is also the target of the cytotoxic T-lymphocyte antigen-4 (CTLA-4) receptor13. Blockade of immune checkpoints by antagonistic antibodies targeting PD-1 or its ligand PD-L1 and CTLA-4 has revolutionized cancer therapy by promoting antitumor immunity14,15. Despite impressive successes, many cancer patients still do not benefit from current immune checkpoint therapies. In this study, we sought to identify novel immune checkpoint pathways and mechanisms that can be targeted for cancer immunotherapy. Immune checkpoint molecules can be regulated at multiple levels. For instance, in addition to transcriptional regulation, post-translational modifications of PD-116 and PD-L117 have been shown to regulate their protein stability and interaction. The turnover of PD-1 is also regulated by its interaction with the E3 ubiquitin ligase FBXO3818. Recently, CD80, the ligand for both CD28 and CTLA-4, was found to interact with PD-L1 in cis on antigen-presenting cells (APCs) to repress the PD-1 and CTLA-4 co-inhibitory pathways while promoting CD28 co-stimulation19,20. Those findings reveal interesting crosstalk between immune checkpoint pathways in regulating T cell activity. Galectin-9 (Gal-9) is a member of the galectin family of animal lectins with conserved carbohydrate-recognition domains (CRDs) for β-galactosides21. Structurally, Gal-9 consists of two CRDs connected by a linker sequence, and is able to crosslink glycoproteins to form multivalent galectin-glycoprotein lattices that regulate multiple cellular processes, including TIM-3-mediated T cell death21,22. Consistent with TIM-3 as a mediator of Gal-9-induced T cell death, terminally exhausted T cells (PD-1+TIM-3+) have reduced long-term survival compared with precursor exhausted T cells that also express PD-1 but lack TIM-3 expression6. Nevertheless, PD-1+TIM-3+ T cells persist in the tumor microenvironment (TME), and even dominate the tumor-infiltrating CD8 T cell pool in some cancer types; their presence is associated with tumor reactivity and predicts response to PD-1 blockade in cancer patients23–26. In this work we reveal a molecular mechanism of exhausted T cell persistence, namely, PD-1 physically interacts with Gal-9 and TIM-3 to attenuate Gal-9/TIM-3-induced T cell apoptosis. In addition, we show upregulation of Gal-9 expression and secretion by interferons, identify tumor-infiltrating immune cells that respond to Gal-9 blockade, and devise an effective combination therapy that boosts the antitumor effect of anti-Gal-9 therapy. Altogether, the current work unravels a role for PD-1 in the regulation of exhausted T cell survival, and establishes Gal-9 as an important regulator of tumor immune response that can be targeted for cancer immunotherapy. RESULTS Galectin-9 is a PD-1-binding protein To further understand the function of PD-1, we sought to identify additional PD-1-binding proteins by expressing a C-terminal 3×FLAG-tagged PD-1 (PD-1.3F) in Jurkat T cells using a doxycycline-inducible retro-lentiviral system27 followed by immunoprecipitation (IP) with a FLAG antibody. Mass spectrometric analysis of the immunocomplexes identified Gal-9 as a major binding protein for PD-1 with known immunomodulatory activity (Supplementary Fig. 1a). This was further validated by IP/Western (Fig. 1a) and pulldown assays with Gal-9 immobilized on Sepharose 4B beads (Fig. 1b). Because Gal-9 is an animal lectin and PD-1 a glycoprotein (Supplementary Fig. 1b), their binding is likely glycan-mediated. Indeed, the addition of lactose, an inhibitor of galectin-glycan interactions, but not sucrose, blocked the binding of Gal-9 to PD-1 (Fig. 1b). To show that the binding is direct and specific, we utilized a plate-based binding assay (Fig. 1c) with purified Fc-fusion proteins of the extracellular domain (ECD) of potential Gal-9-binding proteins and found significant binding of Gal-9 to PD-1 and TIM-3, but not to PD-L1 (Fig. 1d). Other galectins, such as Gal-8 or Gal-1, did not exhibit PD-1-binding activity (Supplementary Fig. 1c). Gal-9 and PD-L1 did not compete with each other for PD-1 binding (Supplementary Fig. 1d, e). In addition, pembrolizumab and nivolumab, the two FDA-approved therapeutic monoclonal antibodies against PD-1, decreased PD-1/PD-L1 binding but not PD-1/Gal-9 binding (Fig. 1e). Thus, the data suggested that the binding sites on PD-1 for Gal-9 are distinct from those for PD-L1 and the two therapeutic antibodies. Together, these results indicated that Gal-9 binding to PD-1 is highly selective and mediated by glycans, and it does not affect PD-1 binding to its cognate ligand PD-L1 or the PD-1 therapeutic antibodies pembrolizumab and nivolumab. [Figure: Galectin-9 is a PD-1-binding protein.a Lysates of Jurkat cells transduced with control lentivirus or PD-1 tagged at the C-terminus with 3× FLAG tag (PD-1.3F) were immunoprecipitated with anti-FLAG magnetic beads and the associated proteins were subjected to immunoblotting with Gal-9 or PD-1 antibodies. The three Gal-9 bands (L, M, S) represent different isoforms resulted from alternative pre-mRNA splicing. b Jurkat PD-1 cell lysates were incubated with glutathione-Sepharose (control) or Gal-9-Sepharose beads with or without sucrose or lactose. Bound proteins were eluted and western blotted with anti-PD-1 antibody. c, d Plate-based binding assay with purified recombinant proteins shows direct and specific binding of PD-1 extracellular domain (ECD) to Gal-9. MaxiSorp plates were coated with Gal-9 and incubated with Fc-fusion protein of the ECD of test binding partners (PD-1, PD-L1, or TIM-3) at various concentrations. Binding was detected by spectrophotometry using an HRP-labeled anti-human IgG (Fc-specific) antibody and the HRP substrate TMB (3,3’,5.5’-tetramethylbenzidine).

Read the complete text